Study
Dupilumab in Older Adults with Atopic Dermatitis: Long-term Safety and Efficacy
This 2024 study found that dupilumab remains safe and effective for older adults with moderate to severe eczema.
Summary
In plain language
Details
Use the full description to understand the study design, methods, and the limits of the findings.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Dupilumab in Older Adults with Atopic Dermatitis: Long-term Safety and Efficacy
Published October 2025
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored April 6, 2026 using rubric v8_2026-03-10.
Assessment
The study is a well-designed multicenter clinical trial focusing on the safety and efficacy of dupilumab in older adults with atopic dermatitis. It is published in a reputable journal, indicating strong methodological quality. However, some details on bias control and statistical methods are not fully accessible, which slightly limits the assessment of these aspects.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 8.3/10 | |
| Statistical methods | 7.5/10 | |
| Reporting completeness | 7.5/10 | |
| Conflicts & funding | 7.5/10 | |
| Replication | 5.0/10 | |
| Relevance to chosen population | 10.0/10 | |
| Journal Reliability | 10.0/10 |
Additional Notes
The study's focus on a senior population is a significant strength, but the lack of full-text access limits the ability to evaluate all methodological details comprehensively.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.